{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:21:06Z","timestamp":1790342466827,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA691"],"award-info":[{"award-number":["22JR5RA691"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["20JR10RA400"],"award-info":[{"award-number":["20JR10RA400"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107331","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:16:07Z","timestamp":1760512567000},"page":"107331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC)"],"prefix":"10.1016","volume":"215","author":[{"given":"Quanwu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2025.107331_bib0001","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Ostrand-Rosenberg S: defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat. Rev. Immunol"},{"issue":"7","key":"10.1016\/j.ejps.2025.107331_bib0002","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1208\/s12249-024-02918-3","article-title":"Concomitant delivery of pirarubicin and salinomycin synergistically enhanced the efficacy of cancer therapy and reduced the risk of cancer relapse","volume":"25","author":"Anees","year":"2024","journal-title":"AAPS. PharmSciTech"},{"issue":"5","key":"10.1016\/j.ejps.2025.107331_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12326","article-title":"The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche","volume":"12","author":"Blavier","year":"2023","journal-title":"J. Extracell. Vesicles"},{"issue":"6","key":"10.1016\/j.ejps.2025.107331_bib0004","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1101\/pdb.prot073411","article-title":"Manual hematoxylin and eosin staining of mouse tissue sections","volume":"2014","author":"Cardiff","year":"2014","journal-title":"Cold. Spring. Harb. Protoc"},{"key":"10.1016\/j.ejps.2025.107331_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-pathmechdis-031521-022116","article-title":"Tumor-derived extracellular vesicles: multifunctional entities in the Tumor microenvironment","volume":"18","author":"Clancy","year":"2023","journal-title":"Annu. Rev. Pathol"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41565-024-01783-2","article-title":"Non-discriminating engineered masking of immuno-evasive ligands on tumour-derived extracellular vesicles enhances tumour vaccination outcomes","volume":"20","author":"Ding","year":"2025","journal-title":"Nat. Nanotechnol"},{"issue":"4","key":"10.1016\/j.ejps.2025.107331_bib0007","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.cclet.2021.10.074","article-title":"Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death","volume":"33","author":"Fu","year":"2022","journal-title":"Chin. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejps.2025.107331_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189024","article-title":"Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?","volume":"1878","author":"Gieleci\u0144ska","year":"2023","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ejps.2025.107331_bib0009","article-title":"Tumor exosomes reprogrammed by low pH are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous Tumor","volume":"8","author":"Gong","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-025-03403-w","article-title":"Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy","volume":"44","author":"Gong","year":"2025","journal-title":"J. Exp. Clin. Cancer. Res"},{"key":"10.1016\/j.ejps.2025.107331_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101325","article-title":"Healing the cornea: exploring the therapeutic solutions offered by MSCs and MSC-derived EVs","volume":"105","author":"Jammes","year":"2025","journal-title":"Prog. Retin. Eye. Res"},{"issue":"4","key":"10.1016\/j.ejps.2025.107331_bib0012","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Fidler-Benaoudia MM: global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/21691401.2018.1548476","article-title":"In-vitro haemocompatibility of dextran-protein submicron particles","volume":"47","author":"Kloypan","year":"2019","journal-title":"Artif. Cells. Nanomed. Biotechnol"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0014","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1038\/s41467-024-52416-0","article-title":"Transvascular transport of nanocarriers for tumor delivery","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun"},{"key":"10.1016\/j.ejps.2025.107331_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122869","article-title":"Engineering cell membrane-camouflaged COF-based nanosatellite for enhanced tumor-targeted photothermal chemoimmunotherapy","volume":"314","author":"Lin","year":"2025","journal-title":"Biomaterials"},{"issue":"785","key":"10.1016\/j.ejps.2025.107331_bib0016","doi-asserted-by":"crossref","first-page":"eadm7269","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13402-024-00969-z","article-title":"Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells","volume":"48","author":"Peppicelli","year":"2025","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.ejps.2025.107331_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108332","article-title":"Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy","volume":"241","author":"Prakash","year":"2023","journal-title":"Pharmacol. Ther"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0019","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12967-024-05457-4","article-title":"Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells","volume":"22","author":"Schioppa","year":"2024","journal-title":"J. Transl. Med"},{"issue":"17","key":"10.1016\/j.ejps.2025.107331_bib0020","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer. Cell"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0022","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA. Cancer. J. Clin"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0023","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA. Cancer. J. Clin"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2219591","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"Sprooten","year":"2023","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0025","article-title":"Immunogenic nanovesicle-tandem-augmented chemoimmunotherapy via efficient cancer-homing delivery and optimized ordinal-interval regime","volume":"10","author":"Sun","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"48","key":"10.1016\/j.ejps.2025.107331_bib0026","doi-asserted-by":"crossref","first-page":"34343","DOI":"10.1074\/jbc.M113.480822","article-title":"Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells","volume":"288","author":"Tadokoro","year":"2013","journal-title":"J. Biol. Chem"},{"issue":"7","key":"10.1016\/j.ejps.2025.107331_bib0027","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends. Cancer"},{"issue":"3","key":"10.1016\/j.ejps.2025.107331_bib0028","article-title":"NADPH selective depletion nanomedicine-mediated radio-immunometabolism regulation for strengthening anti-PDL1 therapy against TNBC","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.ejps.2025.107331_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","author":"Xia","year":"2022","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.ejps.2025.107331_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1525052","article-title":"Prospect of extracellular vesicles in tumor immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front. Immunol"},{"issue":"6","key":"10.1016\/j.ejps.2025.107331_bib0031","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1021\/acsnano.7b01240","article-title":"Pharmaceutical intermediate-modified gold nanoparticles: against multidrug-resistant bacteria and wound-healing application via an electrospun scaffold","volume":"11","author":"Yang","year":"2017","journal-title":"ACS. Nano"},{"issue":"11","key":"10.1016\/j.ejps.2025.107331_bib0032","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/acs.molpharmaceut.5b00536","article-title":"Co-delivery of Pirarubicin and Paclitaxel by Human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers","volume":"12","author":"Yi","year":"2015","journal-title":"Mol. Pharm"},{"issue":"7","key":"10.1016\/j.ejps.2025.107331_bib0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2025.107331_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1528663","article-title":"He S: TRP channels and breast cancer: the role of TRPs in the pathophysiological development","volume":"12","author":"Zhang","year":"2025","journal-title":"Front. Mol. Biosci"},{"issue":"1","key":"10.1016\/j.ejps.2025.107331_bib0035","first-page":"411","article-title":"Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma","volume":"5","author":"Zheng","year":"2015","journal-title":"Am. J. Cancer. Res"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:17:08Z","timestamp":1778775428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872500329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S092809872500329X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107331","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic chemoimmunotherapy using pirarubicin-loaded tumor-derived extracellular vesicles for triple-negative breast cancer (TNBC)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107331"}}